NTI

9.84%

6.7¢ neurotech international limited

The response above is to a comment from @Tony barber.The chart...

First 67 Last

ttppxx

101 Posts.

18/04/24

12:36

Post #: 73405993

Originally posted by ttppxx: ↑
QUESTION:“What was the keycatalyst for Neuron? FDA approval?”

RESPONSE

A) The chart I shared (extracted from NextInvestors) is an exact share price tracker for Neuren Pharmaceuticals, from 2021 toJanuary 2024 (not just 2021). The comments that Next have inserted, show the'catalysts' that preceded (or ‘led’) to the share price re-rates.

B) I have redone this as a table (attached) andextracted additional information from Neuren (just theannouncements). As can be seen, whenmatching events to share price re-rates, the Top 3 SP catalysts were:
1) Trial results (Retts) - (Announced 6th of Dec 2021). This caused the biggestjump to date!
2) FDA approval - (Announced 14th of March 2023). This caused the nextbiggest jump to date.
3) Trial results (Phelan-McDermid) - (Announced 18 Dec 2023). This is not markedon the Next Investors chart - they limited their comments (on the chart) to Rett Syndrome!

DATE
EVENT (CATALYST)
SHARE PRICE MOVES
(5 days)
1
07 Dec 2021
ANN: Positive topline results from Phase 3 trial in Rett syndrome
$1.70 to $4.00 (135%)
2
14 Mar 2023
ANN: FDA approves Daybue - the first treatment for Rett syndrome
$7.60 to $12.80 (68%)
3
18 Dec 2023
ANN: P2 trial shows significant improvements in Phelan-McDermid
$16.00 to $24.00 (50%)
The share price movements within those 2 to 5days post results were much higher than what happened in the interveningperiods: 6% per month rise from Rett P3 results to FDA announcement, and 2.7%per month rice post the FDA announcement up to the P2 Phelan-McDermid trialresults readout.

Indeed, NT1 is still behind. This is shownclearly on the Next Investors chart.
Expand
The response above is to a comment from @Tony barber.

The chart below (from Next Investors) seems well placed as part of a response to the question about catalysts that propelled Neuren to the very high SP that it is now at.

NTI is behind for sure, but still on a path that may have differences, but is not completely dissimilar to how Neuren travelled.

NTI Price at posting: 10.5¢ Sentiment: Buy Disclosure: Held

Upvote

0 Great analysis

Top Stories

SBW

Shekel Brainweigh CEO Nir Leshem weighs in on AI adoption ahead of FY25

BRX

Belararox delineates another porphyry in Argentina at Tambo South

FHE

Frontier Energy achieves key milestone for Waroona energy project

EMD

Emyria's Empax Centre chosen for mental health clinical trial

ASX Market Update: Shares fall flat as GYG soars on debut | 20 June, 2024

With financials holding the fort, materials must step up with some heavy lifting to stimulate stocks

Plagues precede widespread power shifts. We’re living in one – and minerals are at the fore

AML

Cultural heritage agreement puts Walford Creek exploration back on the map

RDN

If you thought lithium was dead, think again. The Pilbara will be central to the next upswing

STX

Strike Energy secures $153 million for Perth Basin gas projects

There are more pages in this discussion • 20 more messages in this thread...

First 67 Last

Add NTI (ASX) to my watchlist

(20min delay)
Last 6.7¢		Change 0.006(9.84%)		Mkt cap ! $68.16M

Open	High	Low	Value	Volume
6.1¢	7.1¢	6.1¢	$140.1K	2.120M

Buyers (Bids)

No.	Vol.	Price($)
1	75000	6.6¢

Sellers (Offers)

Price($)	Vol.	No.
6.7¢	57449	1

View Market Depth

No.	Vol.	Price($)
1	75000	0.066
1	70000	0.065
2	284891	0.064
1	10000	0.062
1	54999	0.061

Price($)	Vol.	No.
0.067	57449	1
0.068	76841	1
0.070	200000	1
0.075	27637	1
0.078	106680	2

Last trade - 16.10pm 21/06/2024 (20 minute delay)

NTI (ASX) Chart

The response above is to a comment from @Tony barber.The chart...

Shekel Brainweigh CEO Nir Leshem weighs in on AI adoption ahead of FY25

Belararox delineates another porphyry in Argentina at Tambo South

Frontier Energy achieves key milestone for Waroona energy project

Emyria's Empax Centre chosen for mental health clinical trial

ASX Market Update: Shares fall flat as GYG soars on debut | 20 June, 2024

With financials holding the fort, materials must step up with some heavy lifting to stimulate stocks

Plagues precede widespread power shifts. We’re living in one – and minerals are at the fore

Cultural heritage agreement puts Walford Creek exploration back on the map

If you thought lithium was dead, think again. The Pilbara will be central to the next upswing

Strike Energy secures $153 million for Perth Basin gas projects

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

	DATE	EVENT (CATALYST)	SHARE PRICE MOVES (5 days)
1	07 Dec 2021	ANN: Positive topline results from Phase 3 trial in Rett syndrome	$1.70 to $4.00 (135%)
2	14 Mar 2023	ANN: FDA approves Daybue - the first treatment for Rett syndrome	$7.60 to $12.80 (68%)
3	18 Dec 2023	ANN: P2 trial shows significant improvements in Phelan-McDermid	$16.00 to $24.00 (50%)

The response above is to a comment from @Tony barber.The chart...

Top Stories

Shekel Brainweigh CEO Nir Leshem weighs in on AI adoption ahead of FY25

Belararox delineates another porphyry in Argentina at Tambo South

Frontier Energy achieves key milestone for Waroona energy project

Emyria's Empax Centre chosen for mental health clinical trial

ASX Market Update: Shares fall flat as GYG soars on debut | 20 June, 2024

With financials holding the fort, materials must step up with some heavy lifting to stimulate stocks

Plagues precede widespread power shifts. We’re living in one – and minerals are at the fore

Cultural heritage agreement puts Walford Creek exploration back on the map

If you thought lithium was dead, think again. The Pilbara will be central to the next upswing

Strike Energy secures $153 million for Perth Basin gas projects

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News